We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.80 | -1.07% | 167.00 | 70,598 | 12:22:25 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 166.40 | 167.00 | 168.60 | 166.60 | 168.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Home Health Care Services | USD 65.12M | USD -65.7M | USD -0.2744 | -6.12 | 404.14M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:21:29 | AT | 90 | 167.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/12/2024 | 07:00 | UK RNS | PureTech Health PLC PRTC Presents LYT-200 Phase 1b Data in AML at ASH |
| 04/12/2024 | 18:15 | ALNC |  TOP NEWS: Retail pair and under-pressure Vistry booted out of FTSE 100 |
| 27/11/2024 | 17:31 | UK RNS | PureTech Health PLC Holding(s) in Company |
| 27/11/2024 | 17:30 | UK RNS | PureTech Health PLC Holding(s) in Company |
| 20/11/2024 | 12:05 | UK RNS | PureTech Health PLC PRTC's Seaport Adds Microsoft and J&J Exec to BOD |
| 05/11/2024 | 12:05 | UK RNS | PureTech Health PLC PRTC's Seaport Adds Biotech Finance Exec as CFO |
| 01/11/2024 | 07:00 | UK RNS | PureTech Health PLC Total Voting Rights |
| 31/10/2024 | 17:00 | UK RNS | PureTech Health PLC Director/PDMR Shareholding |
| 30/10/2024 | 11:00 | UK RNS | PureTech Health PLC PRTC to Present at UBS and Jefferies Conferences |
| 21/10/2024 | 06:00 | UK RNS | PureTech Health PLC PRTC's Seaport Closes $225M Series B Financing |
Puretech Health (PRTC) Share Charts1 Year Puretech Health Chart |
|
1 Month Puretech Health Chart |
Intraday Puretech Health Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/12/2024 | 12:19 | PureTech Health - innovative healthcare | 2,603 |
| 22/7/2018 | 20:35 | PureTech Health (PRTC) One to Watch Monday | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 12:21:29 | 167.00 | 90 | 150.30 | AT |
| 12:21:29 | 167.00 | 118 | 197.06 | AT |
| 12:21:02 | 167.00 | 1,206 | 2,014.02 | AT |
| 12:21:02 | 167.00 | 19 | 31.73 | AT |
| 12:21:02 | 167.00 | 7 | 11.69 | AT |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by Puretech Health Daily Update Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 168.80p.Puretech Health currently has 239,421,312 shares in issue. The market capitalisation of Puretech Health is £402,227,804. Puretech Health has a price to earnings ratio (PE ratio) of -6.12. This morning PRTC shares opened at 168.60p |
Posted at 05/12/2024 08:13 by peterm35 Assuming PRTC get the LYT100 and 200 study details out in Q4 as suggested, then we only have 13 working days left till Christmas, can't imagine they will publish between Xmas and NY. Really not long to wait now. |
Posted at 23/11/2024 10:43 by takeiteasy "PureTech Health certainly appears significantly undervalued. However, for a traditional investor looking at earnings multiples or dividend yield, valuing PureTech is tricky. As with many biotech companies, there is little revenue and substantial annual losses, and it's unclear how an investor will realise this value. In addition, the recent share tender offer left a perceived overhang, and the shares have been heavily sold off."I would like to think the firm is addressing this in two specific areas that I can see. Ensure they get a share of recurring sales income from drug developments they sell to big pharma alongside having entities within the group launced via IPOs that have a public rather than private status so analysts can impute direct market values for PRTC's retained % holding rather than rely on estimates. Given the scale of undervaluation has been shown by a number of analysts to be so great any hint now of a plan or path to addressing this MAY be enough for a rethink of the opportunity (choose words carefully here) I would like us to become more like the BG USA trust model of a public and private equity split within the portfolio :) nai etc |
Posted at 30/10/2024 14:07 by takeiteasy Seaport announcements a master stroke in my book i.e. ensure a well over subscribed funding round and then follow up to the IIs with the message if you want more of the Seaport exposure without having to wait for the next funding round then buy some/more PRTC ... and heh presto PRTC price shoots up ..lols...:)nai etc |
Posted at 06/10/2024 03:54 by ohisay Liberum in their figurings late last year had LYT100 unrisked at 380m$.If my maths is correct that works out at £1.20p per share to PRTC . Given that theres nothing much in the current share price for that atm, one might reasonably expect an extra £1 per share in a success case. They say .. Depending on the outcome of the ELEVATE IPF Phase IIb trial, we believe that LYT-100 has >$1bn sales potential and LYT-100 would be attractive to a potential licensing partner, whether that be a company looking to enter the field or an existing player like Roche, who might see LYT-100 as an attractive means to extend its market position with a new potential backbone therapy |
Posted at 25/9/2024 06:53 by takeiteasy Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical DataTipRanks Sep. 23, 2024, 05:15 AM BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $48.00. Evan Seigerman has given his Hold rating due to a combination of factors, notably the anticipation that KarXT’s approval is already reflected in the current market price of Bristol-Myers Squibb’s shares. He acknowledges that while the approval of KarXT is expected given its strong clinical data, the actual impact on the stock will depend on the specifics of the drug’s label and the company’s ability to execute a successful launch. Seigerman also points out that a label without the black box warning typically associated with antipsychotics could provide a slight upside, but that this potential benefit appears to be accounted for in the stock’s valuation. hxxps://markets.busi So chaps, does our share price already reflect approval for Karxt? |
Posted at 06/9/2024 07:20 by return_of_the_apeman Indeed fantastic news and it opened downI would like the cash coming from the first milestone payment to be deployed, for example as another buyback to support the share price and so we all get a bigger share of what is going to be a very rewarding company one day The price will be under cash on the books come the expected milestone payment? and although a predator would have to pay a premium they could buy the majority of this up using Purtech's own cash if the board are not careful |
Posted at 26/7/2024 06:55 by takeiteasy Tbf the share price has been royally punished and BOD have missed out on just about all of the Russell2000/biotech mini boom over the past few weeks. So hopefully they realise their mea culpa and the price us as shareholders pay for their mistakes :) |
Posted at 25/7/2024 07:40 by ashkv At 167p - a market cap of GBP 400.64 million per Google Finance or at GBPUSD 1.29 Market Cap is US$516.8 million in dollar terms!!Net Cash of PRTC is US$ 473.3 million or nearly 92% of market cap (US$ 473.3mn/ US$516.8mn) equivalent to 153.2p!!! PRTC doesn't have any debt!!! NO VALUE TO UPCOMING ROYALTY STREAM OF US$400 million, other investments or drugs in development!!! GREAT TIME TO ANNOUNCE FURHTER BUYBACKS!!! Share price down nearly 1/3 since recent 250p tender offer!!! Nearly 50% upside at present levels to 250p recently concluded tender offer!!! |
Posted at 03/7/2024 14:17 by bahiflyer I'm amazed Invesco still have so many left. They've been drip feeding them down for the last 3 years or so it seems. Rather than buy backs, which did nothing for the share price last time, PRTC should open a dialogue with Invesco to find out what holding they'd be happy to stop selling at and either buy off them direct or find an alternative II to have an interest. That would be much easier to instigate if there was an actual dividend policy, which is after all the only long term way of returning money to shareholders directly, and that's what income funds want, which in turn would stimulate overall share price growth. It's something a decent PR team or advisers would point out to them |
Posted at 21/3/2024 10:33 by wassapper So please help me here. The tender offer will be at 250p per share (if it proceeds)?Current share price is 222p So if I buy more now (to add to my goodly amount), sometime in April/May, I'll be offered 250p a share for some of my shares by the company? Do I make an "instant" 28p per share or just for a proportion? If so why aren't more share being bought? What happends to the share price after the tender offer (all things being equal)? Does it drop like a typical ex-divi action? First time tender for me so quite confused. I am sure many of these questions will be asked again! Thanks! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
